Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is listed as one of the 13 Best Low Risk High Growth Stocks to Buy. Analyst sentiments are mixed following the presentation of preclinical data for BP1.15205, a potential game-changer for the company’s pipeline.

Headquartered in New Jersey, Harmony Biosciences is focused on developing therapies for rare neurological and sleep disorders. Their lead product, WAKIX® (pitolisant), treats excessive daytime sleepiness in narcolepsy. The company also has pipeline treatments for Prader‑Willi Syndrome and myotonic dystrophy.

On June 11, 2025, Harmony Biosciences announced new preclinical data for BP1.15205, a potential best-in-class orexin-2 agonist with promising wake-promoting effects. Analysts from Mizuho Securities and H.C. Wainwright maintain a Buy rating, while Deutsche Bank raises the price target to $55. Goldman Sachs, however, remains at a Hold rating.

Despite mixed ratings, Harmony Biosciences maintains its position as a low-risk stock with high growth potential, offering a beta of 0.84 and an EPS growth of 25.93% for the next five years. Investors are advised to consider other AI stocks with potentially greater upside and less downside risk.

Read more at Yahoo Finance: Harmony Biosciences Advances Pipeline While Navigating Analyst Caution